Menarini CEO Elcin Barker Ergun says she found Insilico’s generative AI platform “one of the most advanced” among its peers. The technology promises to cut down the time and cost involved in early-stage drug development, but has yet to yield a successful drug. The Latvian scientist says Insilico’s AI platforms can produce a drug candidate that’s ready for human trials in about 20 months, at least twice as fast than the traditional approach. Its lead candidate, a potential drug for idiopathic pulmonary fibrosis, an incurable lung disease, is in mid-stage human trials in the U.S. and China. To keep Insilico in the race to develop the world’s first AI-discovered drug, the startup filed for a Hong Kong initial public offering in June.

Source: Forbes January 17, 2024 20:22 UTC